This grant supports activities contributing to an innovative, sustainable, and competitive EU health industry focusing on cell-free protein synthesis (CFPS) platforms for the discovery and/or production of biologicals. Expected outcomes include improved access for biopharmaceutical industries to streamlined development and production processes for peptide- or protein-based biologicals, health systems benefiting from enhanced or decentralized production systems, and improved access, availability, and affordability of pharmaceuticals for citizens and patients. Proposals should address at least two of the following elements: addressing bottlenecks in large-scale CFPS deployment, using synthetic biology for the design and screening of de-novo biomolecules, and developing or optimizing CFPS platforms to Good Manufacturing Practices (GMP) for clinical-grade material production, with demonstration of superiority over current systems considered an asset.
| Agency | HORIZON (EU) |
|---|---|
| Region | EU |
| Country | N/A |
| Legal form | Company, NGO, Government organization, Other |
| Start date | 10 Feb 2027 |
| End date | 13 Apr 2027 |
| Max funding | €6,000,000 - €8,000,000 per grant |
| Budget | €24,500,000 (for this topic in 2027) |
| Coverage | Grant covers eligible costs; refer to Horizon Europe rules for details. |